ESR1 gene variants affect FSHR-depended risk of fibrocystic mastopathy in infertile women
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-3.16468Keywords:
ESR1, FSHR, infertility, mastopathyAbstract
Summary. Background: The infertile women have an increased risk of developing benign and malignant tumors, in particular, breast cancer. Most studies have examined the role of gene variants in the risk of developing breast cancer, but there is little evidence of genetic risk factors for benign tumors. Aim: To assess the combined genetic risk of developing mastopathy in women with FSHR (rs6165, rs6166) and ESR1 (rs9340799, rs2234693) gene variants. Materials and Methods: The study included 87 infertile women (45 with concomitant fibrocystic mastopathy and 42 without mastopathy). Results: For rs9340799 and rs2234693 variants of the ESR1 gene, we did not find any significant differences in the distribution of genotypes in infertile women with or without mastopathy. In patients with mastopathy, there was a reliable increase in the frequency of 307Ala/Ala and 680Ser/Ser genotypes of FSHR gene (χ2 = 6.39, p = 0.012, OR = 4.49 (1.48–13.65)) as compared to patients without mastopathy. In the presence of 307Thr/Thr and 680Asn/Asn genotypes of the FSHR gene, a 4.88-fold reduction of mastopathy risk (χ2 = 8.06, p = 0.005, OR = 0.21(0.07–0.59)) was observed. The frequency of the FSHR and the ESR1 genotypes combinations — 307Thr/Thr+680Asn/Asn+351AG+397TC was significantly decreased in patients with mastopathy. Conclusions: Our study did not find an association of ESR1 gene variants with the risk of developing of mastopathy in infertile women although heterozygous variants of the ESR1 gene enhanced the “protective” effect of FSHR gene variants and reduced the risk of mastopathy.
References
Feng J, Wang J, Zhang Y, et al. The efficacy of complementary and alternative medicine in the treatment of female infertility. Evid Based Complement Alternat Med 2021; 2021: 6634309. https://doi.org/10.1155/2021/6634309.
Murugappan G, Li S, Lathi RB, et al. Risk of cancer in infertile women: analysis of US claims data. Hum Reprod 2019; 34: 894–902. https://doi.org/10.1093/humrep/dez018.
Williams CL, Jones ME, Swerdlow AJ, et al. Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991–2010: data linkage study including 2.2 million person years of observation. BMJ 2018; 362: k2644. https://doi.org/10.1136/bmj.k2644.
Jensen A, Sharif H, Olsen JH, et al. Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. Am J Epidemiol 2008; 168: 49–57. https://doi.org/10.1093/aje/kwn094.
Al-Eitan LN, Rababa’h DM, Alghamdi MA, et al. Association between ESR1, ESR2, HER2, UGT1A4, and UGT2B7 polymorphisms and breast cancer in Jordan: a case-control study. BMC Cancer 2019; 19: 1257. https://doi.org/10.1186/s12885-019-6490-7.
Hu X, Jiang L, Tang C, et al. Association of three single nucleotide polymorphisms of ESR1with breast cancer susceptibility: a meta-analysis. J Biomed Res 2017; 31: 213–25. https://doi.org/10.7555/JBR.31.20160087.
Henriksen LS, Hagen CP, Assens M, et al. Genetic variations in FSH action affect sex hormone levels and breast tissue size in infant girls: a pilot study. J Clin Endocrinol Metab 2016; 101: 3191-8. https://doi.org/10.1210/jc.2016-1672.
Paliychuk OV, Polishchuk LZ, Rossokha ZI, et al. Molecular-genetic models for prognosis of development of tumors of reproductive system in women with family history of cancer. Exp Oncol 2018; 40: 59–67.
Kornatskа AG, Gorovenko NG, Dubenko OD, et al. [Genetic risk factor for fibrocystic breast disease in women with infertility]. Health of Woman 2016; 1: 187–91 (in Ukrainian). https://doi.org/10.15574/HW.2016.107.187.
Fishchuk L, Rossokha Z, Sheyko L, et al. ESR1 gene related risk in the development of idiopathic infertility and early pregnancy loss in married couples. Georgian Med News 2020; 6: 48–54.
Sambor IY, Rossokha ZI, Medvedieva NM, et al. [Genetics aspects of premature ovarian failure development (literature review)]. Obstetrics. Gynecology. Genetics 2018; 4: 52–59 (in Ukrainian).
Tatarchuk TF, Hiulmamedova ID, Rossokha ZI, et al. [Pregnancy and childbirth after a cycle of assisted reproductive technologies in patient with a mutation of FSH receptor gene, secondary amenorrhea, uterine hypoplasia and endometrial receptivity disorders (clinical case)]. Reprod Endocrinol 2015; 6: 72–5 (in Russian).
Alexa O, Stolnicu S, Horváth E, et al. [The relationship between benign breast proliferation (fibrocystic mastopathy) and the appearance of breast carcinoma]. Rev Med Chir Soc Med Nat Iasi 2000; 104: 101–9 (in Romanian).
Schauer K. [Fibrocystic mastopathy as a cancer risk]. Zentralbl Chir 1989; 114: 11–7; discussion 18–9 (in German).
Lundberg FE, Johansson AL, Rodriguez-Wallberg K, et al. Association of infertility and fertility treatment with mammographic density in a large screening-based cohort of women: a cross-sectional study. Breast Cancer Res 2016; 18: 36. https://doi.org/10.1186/s13058-016-0693-5.
Zalewski G, Wołczyński S, Chyczewski L. Association of rs6166 polymorphism with FSH receptor transcript variants and steroid production in human granulosa cell cultures. Syst Biol Reprod Med 2013; 59: 191–8. https://doi.org/10.3109/19396368.2012.745035.
Garde SV, Sheth AR, Joseph R, et al. Occurrence and de novo biosynthesis of follicle stimulating hormone (FSH) in benign and malignant conditions of human breast. Cancer Lett 1993; 75: 1–9. https://doi.org/10.1016/0304-3835(93)90200-s.
Zhou J, Chen Y, Huang Y, et al. Serum follicle-stimulating hormone level is associated with human epidermal growth factor receptor type 2 and Ki67 expression in post-menopausal females with breast cancer. Oncol Lett 2013; 6: 1128–32. https://doi.org/10.3892/ol.2013.1516.
Valkenburg O, van Santbrink EJ, König TE, et al. Follicle-stimulating hormone receptor polymorphism affects the outcome of ovulation induction in normogonadotropic (World Health Organization class 2) anovulatory subfertility. Fertil Steril 2015; 103: 1081-8.e3. https://doi.org/10.1016/j.fertnstert.2015.01.002.
Lerner-Geva L, Keinan-Boker L, Blumstein T, et al. Infertility, ovulation induction treatments and the incidence of breast cancer-a historical prospective cohort of Israeli women. Breast Cancer Res Treat 2006; 100: 201–12. https://doi.org/10.1007/s10549-006-9238-4.
Kwon CY, Cho IH, Park KS. Therapeutic effects and mechanisms of herbal medicines for treating polycystic ovary syndrome: a review. Front Pharmacol 2020; 11: 1192. https://doi.org/10.3389/fphar.2020.01192.
Jin J, Hu QY, Xu WW, et al. Tanshinone IIA attenuates estradiol-induced polycystic ovarian syndrome in mice by ameliorating FSHR expression in the ovary. Exp Ther Med 2019; 17: 3501–8. https://doi.org/10.3892/etm.2019.7352.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
